Free-threaded Python is now officially supported, though using it remains optional. Here are four tips for developers getting ...

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.

Lilly takes POINT in radiopharma push Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.